Payment overview · 2025
General Payments
$809.77
46 reported records · 10 companies
Healthcare provider profile · identity verified
Janice Siciliano
Allopathic & Osteopathic Physicians|Internal Medicine · SEA GIRT, NJ · NPI 1689612129
Verified facts
What the public records show
CMS Open Payments records show Janice Siciliano received $809.77 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $261.68 | 32.3% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.72 | 18.9% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $128.56 | 15.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.76 | 8.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.79 | 7.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.35 | 5.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.70 | 4.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.52 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.48 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.21 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $809.77 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.69 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $128.56 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.06 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.33 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.33 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.79 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $47.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.35 | 3 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 102 |
| Metformin Hcl | Metformin Hcl | 355 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 73 |
| Alprazolam | Alprazolam | 223 | 69 |
| Simvastatin | Simvastatin | 176 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 38 |
| Lisinopril | Lisinopril | 137 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 40 |
| Sertraline Hcl | Sertraline Hcl | 131 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 35 |
| Valsartan | Valsartan | 120 | 38 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 118 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 36 |
| Ozempic | Semaglutide | 112 | 17 |
| Losartan Potassium | Losartan Potassium | 99 | 33 |
| Allopurinol | Allopurinol | 86 | 23 |
| Mounjaro | Tirzepatide | 83 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 19 |
| Tramadol Hcl | Tramadol Hcl | 79 | 14 |
| Synthroid | Levothyroxine Sodium | 78 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 17 |
| Farxiga | Dapagliflozin Propanediol | 65 | 17 |
| Carvedilol | Carvedilol | 64 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 23 |
| Enalapril Maleate | Enalapril Maleate | 60 | 17 |
| Omeprazole | Omeprazole | 60 | 19 |
| Azithromycin | Azithromycin | 59 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 27 |
| Methylprednisolone | Methylprednisolone | 57 | 53 |
| Gabapentin | Gabapentin | 56 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 23 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 54 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 20 |
| Montelukast Sodium | Montelukast Sodium | 53 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 14 |
| Prednisone | Prednisone | 50 | 33 |
| Telmisartan | Telmisartan | 49 | 12 |
| Jardiance | Empagliflozin | 48 | 13 |
| Clonazepam | Clonazepam | 45 | 11 |
| Trazodone Hcl | Trazodone Hcl | 45 | 12 |
| Famotidine | Famotidine | 42 | 19 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 39 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Furosemide | Furosemide | 33 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 11 |
| Amoxicillin | Amoxicillin | 28 | 25 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | 17 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 17 |
| Concerta | Methylphenidate Hcl | 22 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $809.77 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LAGEVRIO, MOUNJARO, Ozempic, REXULTI, Rybelsus, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error